Clinical trial · Interventional
Efficacy of Distilled Water Versus Mitomycin C on Preventing Recurrences of Bladder Cancer After Transurethral Resection
The Efficacy of Distilled Water vs Mitomycin C as a Single Dose Immediate Instillation After Transurethral Resection of Intermediate Risk, Recurrent Superficial Bladder Cancer
NCT00816075CI-TRIAL-00002058unknownPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to compare and evaluate the efficacy of distilled water vs Mitomycin C on preventing the recurrences of intermediate risk group recurrent superficial bladder cancer administered as a single dose immediate instillation after complete Transurethral Resection(TUR) of the tumor.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Distilled Water | — | UNRESOLVED | — |
| Recurrent Superficial Bladder Cancer | Non-Muscle Invasive Bladder Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| distilled water | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1, Distilled water
- description
- the group of patients with superficial bladder cancer in the intermediate risk group who had their first recurrence after 6 months from the initial TUR. We plan to administer 200 ml of distilled water as immediate instillation for 2 hours
- interventionNames
- Drug: distilled water
Primary outcomes (1)
- measure
- tumor recurrence by cystoscopic examination, urine and bladder wash cytology
- timeFrame
- within two years after instillation
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * pathologic finding of superficial bladder cancer within the intermediate risk group * recurred after 6 months from the primary tumor * those patients who were included in our follow-up program since 2002 and whose records could be obtained. Exclusion Criteria: * carcinoma in situ * any form of intracavitary maintenance therapy * any form of bladder cancer other than transitional cell type
References
Publications (0)
Data not yet available
No reference posted for this study.